Lowest Price Guaranteed
Pages
198
Last Updated
June 2026
View Count
12432
1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Introduction
2.4.2.2. Types
2.4.2.2.1. Qualitative
2.4.2.2.2. Quantitative
2.4.2.3. Advantages
2.4.2.4. Techniques
2.4.2.4.1. Interviews
2.4.2.4.2. Surveys
2.4.2.4.3. Focus Groups
2.4.2.4.4. Observational Research
2.4.2.4.5. Social Media Interactions
2.4.2.5. Stakeholders
2.4.2.5.1. Company Executives (CXOs)
2.4.2.5.2. Board of Directors
2.4.2.5.3. Company Presidents and Vice Presidents
2.4.2.5.4. Key Opinion Leaders
2.4.2.5.5. Research and Development Heads
2.4.2.5.6. Technical Experts
2.4.2.5.7. Subject Matter Experts
2.4.2.5.8. Scientists
2.4.2.5.9. Doctors and Other Hospitals
2.4.2.6. Ethics and Integrity
2.4.2.6.1. Research Ethics
2.4.2.6.2. Data Integrity
2.4.3. Analytical Tools and Databases
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Forecast Methodology
3.1.1. Top-Down Approach
3.1.2. Bottom-Up Approach
3.1.3. Hybrid Approach
3.2. Market Assessment Framework
3.2.1. Total Addressable Market (TAM)
3.2.2. Serviceable Addressable Market (SAM)
3.2.3. Serviceable Obtainable Market (SOM)
3.2.4. Currently Acquired Market (CAM)
3.3. Forecasting Tools and Techniques
3.3.1. Qualitative Forecasting
3.3.2. Correlation
3.3.3. Regression
3.3.4. Time Series Analysis
3.3.5. Extrapolation
3.3.6. Convergence
3.3.7. Forecast Error Analysis
3.3.8. Data Visualization
3.3.9. Scenario Planning
3.3.10. Sensitivity Analysis
3.4. Key Considerations
3.4.1. Demographics
3.4.2. Market Access
3.4.3. Reimbursement Scenarios
3.4.4. Industry Consolidation
3.5. Robust Quality Control
3.6. Key Market Segmentations
3.7. Limitations
4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Overview of Major Currencies Affecting the Market
4.2.2.2. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Exchange Impact
4.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
4.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Overview of Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product (GDP)
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. R&D Innovation
4.2.11.7. Stock Market Performance
4.2.11.8. Supply Chain
4.2.11.9. Cross-Border Dynamics
5. EXECUTIVE SUMMARY
6. INTRODUCTION
6.1. Chapter Overview
6.2. Overview of Polycystic Ovary Syndrome
6.2.1. Polycystic Ovary Syndrome: Signs and Symptoms
6.2.2. Key Therapies and Drug Classes for Polycystic Ovary Syndrome Management
6.2.3. Challenges Associated with Polycystic Ovary Syndrome Management
6.3. Future Perspective
7. Pipeline Review
7.1. Chapter Overview
7.2. Polycystic Ovary Syndrome: Drug Development Pipeline
7.3. Polycystic Ovary Syndrome: Drug Pipeline Analysis
7.3.1. Analysis by Phase of Development
7.3.2. Analysis by Drug Class
7.3.3. Analysis by Symptoms Treated
7.3.4. Analysis by Drug Class and Symptoms Treated
7.3.5. Analysis by Line of Treatment
7.3.6. Analysis by Route of Administration
7.4. Polycystic Ovary Syndrome: Developers
7.4.1. Analysis by Year of Establishment
7.4.2. Analysis by Company Size
7.4.3. Analysis by Geographical Location
7.4.4. Analysis by Type of Player
7.4.5. Analysis by Most Active Players
7.4.6. Analysis by Drug Class
8. COMPANY PROFILES
8.1. Chapter Overview
8.2. AbbVie (US)
8.2.1. Company Overview
8.2.2. Financial Information
8.2.3. Service / Product Portfolio
8.2.4. Recent Developments and Future Outlook
* Similar details are presented for other below mentioned companies based on information in the public domain
8.3. Bayer (Germany)
8.4. GlaxoSmithKline (UK)
8.5. Lupin Pharmaceuticals (India)
8.6. Merck (US)
8.7. Pfizer (US)
8.8. Takeda (Japan)
8.9. Teva Pharmaceuticals (Israel)
9. KOL ANALYSIS
10. GRANT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Polycystic Ovary Syndrome: List of Academic Grants
10.3.1. Analysis by Project Start Year
10.3.2. Analysis by Focus Area
10.3.3. Analysis by Support Period
10.3.4. Analysis by Type of Grant
10.3.5. Analysis by Amount Awarded
10.3.6. Analysis by Study Section
10.3.7. Analysis by Drug Class
10.3.8. Analysis by Route of Administration
10.3.9. Leading Funding Institutes: Analysis by Number of Grants
10.3.10. Leading Recipient Organizations: Analysis by Number of Grants
11. CLINICAL TRIALS ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Polycystic Ovary Syndrome: Clinical Trial Analysis
11.3.1. Analysis by Trial Registration Year
11.3.2. Analysis of Number of Patients Enrolled by Trial Registration Year
11.3.3. Analysis by Trial Phase
11.3.4. Analysis of Number of Patients Enrolled by Trial Phase
11.3.5. Analysis by Trial Status
11.3.6. Analysis by Trial Registration Year and Trial Status
11.3.7. Analysis by Target Patient Population
11.3.8. Analysis by Study Design
11.3.8.1. Analysis by Type of Allocation
11.3.8.2. Analysis by Type of Intervention Model
11.3.8.3. Analysis by Type of Masking
11.3.8.4. Analysis by Trial Purpose
11.3.9. Analysis by Type of Sponsor / Collaborator
11.3.10. Leading Players: Analysis by Number of Clinical Trials
11.3.11. Analysis by Geography
11.3.11.1. Analysis of Clinical Trials by Geography
11.3.11.2. Analysis of Clinical Trials by Geography and Trial Status
11.3.11.3. Analysis of Patients Enrolled by Geography and Trial Status
12. PATENT ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Polycystic Ovary Syndrome: Patent Analysis
12.3.1. Analysis by Publication Year
12.3.2. Analysis by Geographical Location
12.3.3. Analysis by CPC Classifications
12.3.4. Emerging Focus Areas
12.3.5. Leading Players: Analysis by Number of Patents
12.4. Polycystic Ovary Syndrome Drugs: Patent Benchmarking Analysis (Industry Players)
12.4.1. Analysis by Patent Characteristics
12.4.2. Analysis by Geographical Location
12.5. Polycystic Ovary Syndrome: Patent Valuation Analysis
12.6. Leading Patents: Analysis by Number of Citations
13. MARKET IMPACT ANALYSIS
13.1. Chapter Overview
13.2. Market Drivers
13.3. Market Restraints
13.4. Market Opportunities
13.5. Market Challenges
13.6. Conclusion
14. GLOBAL POLYCYSTIC OVARY SYNDROME MARKET
14.1. Chapter Overview
14.2. Key Assumptions and Methodology
14.3. Trends Disruption Impacting Market
14.4. Global Polycystic Ovary Syndrome Market, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
14.5. Multivariate Scenario Analysis
14.5.1. Conservative Scenario
14.5.2. Optimistic Scenario
14.6. Key Market Segmentations
15. MARKET OPPORTUNITIES BASED ON TYPE OF DRUG CLASS
15.1. Chapter Overview
15.2. Key Assumptions and Methodology
15.3. Revenue Shift Analysis
15.4. Market Movement Analysis
15.5. Penetration-Growth (P-G) Matrix
15.6. Polycystic Ovary Syndrome Market for Immune-Sensitizing Agents: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
15.7. Polycystic Ovary Syndrome Market for Oral Contraceptives: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
15.8. Polycystic Ovary Syndrome Market for Anti-Androgens: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
15.9. Polycystic Ovary Syndrome Market for Anti-Obesity: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
15.10. Data Triangulation and Validation
14. MARKET OPPORTUNITIES BASED ON ROUTE OF ADMINISTRATION
14.1. Chapter Overview
14.2. Key Assumptions and Methodology
14.3. Revenue Shift Analysis
14.4. Market Movement Analysis
14.5. Penetration-Growth (P-G) Matrix
14.6. Polycystic Ovary Syndrome Market for Oral: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
14.7. Polycystic Ovary Syndrome Market for Subcutaneous: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
14.8. Polycystic Ovary Syndrome Market for Intravenous: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
14.9. Polycystic Ovary Syndrome Market for Others: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
14.10. Data Triangulation and Validation
15. MARKET OPPORTUNITIES BASED ON TYPE OF SURGERY
15.1. Chapter Overview
15.2. Key Assumptions and Methodology
15.3. Revenue Shift Analysis
15.4. Market Movement Analysis
15.5. Penetration-Growth (P-G) Matrix
15.6. Polycystic Ovary Syndrome Market for Ovarian Wedge Resection: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
15.7. Polycystic Ovary Syndrome Market for Laparoscopic Ovarian Drilling: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
15.8. Data Triangulation and Validation
16. MARKET OPPORTUNITIES BASED ON DISTRIBUTION CHANNEL
16.1. Chapter Overview
16.2. Key Assumptions and Methodology
16.3. Revenue Shift Analysis
16.4. Market Movement Analysis
16.5. Penetration-Growth (P-G) Matrix
16.6. Polycystic Ovary Syndrome Market for Hospital Pharmacy: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
16.7. Polycystic Ovary Syndrome Market for Drug Store and Retail Pharmacy: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
16.8. Polycystic Ovary Syndrome Market for Online Providers: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
16.9. Data Triangulation and Validation
17. MARKET OPPORTUNITIES FOR POLYCYSTIC OVARY SYNDROME IN NORTH AMERICA
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Revenue Shift Analysis
17.4. Market Movement Analysis
17.5. Penetration-Growth (P-G) Matrix
17.6. Polycystic Ovary Syndrome Market in North America: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
17.6.1. Polycystic Ovary Syndrome Market in the US: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
17.6.2. Polycystic Ovary Syndrome Market in Canada: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
17.7. Data Triangulation and Validation
18. MARKET OPPORTUNITIES FOR POLYCYSTIC OVARY SYNDROME IN EUROPE
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Revenue Shift Analysis
18.4. Market Movement Analysis
18.5. Penetration-Growth (P-G) Matrix
18.6. Polycystic Ovary Syndrome Market in Europe: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
18.6.1. Polycystic Ovary Syndrome Market in UK: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
18.6.2. Polycystic Ovary Syndrome Market in France: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
18.6.3. Polycystic Ovary Syndrome Market in Italy: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
18.6.4. Polycystic Ovary Syndrome Market in Spain: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
18.7. Data Triangulation and Validation
19. MARKET OPPORTUNITIES FOR POLYCYSTIC OVARY SYNDROME IN ASIA-PACIFIC and ROW
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Revenue Shift Analysis
19.4. Market Movement Analysis
19.5. Penetration-Growth (P-G) Matrix
19.6. Polycystic Ovary Syndrome Market in Asia-Pacific and ROW: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
19.6.1. Polycystic Ovary Syndrome Market in China: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
19.6.2. Polycystic Ovary Syndrome Market in India: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
19.6.3. Polycystic Ovary Syndrome Market in Australia: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
19.6.4. Polycystic Ovary Syndrome Market in Japan: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
19.7. Polycystic Ovary Syndrome Market in ROW: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
19.8. Data Triangulation and Validation
20. APPENDIX 1: TABULATED DATA
21. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
22. CUSTOMIZATION OPPORTUNITIES
23. ROOTS SUBSCRIPTION SERVICES
24. AUTHOR DETAIL